Biosensors Journal
Open Access

Research Article

A New Chemiluminescent Enzyme Immunoassay for Plasma Tissue Factor Detection

Yuki Fujiwara^1,2, Yoshikatsu Koga¹, Kimiko Hasegawa³, Hiroya Fujii³, Tetsuji Yamaguchi³, Ryou Tsumura^1,2, Masahiro Yasunaga¹and Yasuhiro Matsumura^1,2*

¹Division of Developmental Therapeutics, Research Centre for Innovative Oncology, National Cancer Centre Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan

²Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa, Chiba, Japan

³JSR Life Sciences, R&D Department Unit 1, 25 Miyukigaoka, Tsukuba, Ibaraki, Japan

Corresponding Author:

Yasuhiro Matsumura
Division of Developmental Therapeutics
Research Centre for Innovative Oncology
National Cancer Centre Hospital East
6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
Tel: 04- 7134-6857
E-mail: yhmatsum@east.ncc.go.jp

Received Date: October 23, 2014; Accepted Date: November 26, 2014; Published Date: December 03, 2014

Citation: Fujiwara Y, Koga Y, Hasegawa K, Fujii H, Yamaguchi T, et al. (2014) A New Chemiluminescent Enzyme Immunoassay for Plasma Tissue Factor Detection. Biosens J 3:111. doi: 10.4172/2090-4967.1000111

Copyright: © 2014 Fujiwara Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

High concentrations of tissue factor (TF) in the plasma may have a major role in the elevated risk of thrombosis in patients with malignant diseases. The quantification of plasma TF concentrations in cancer patients may enable accurate assessments of the risk of thrombosis during the process of cancer progression. Whether the plasma TF concentration is associated with the tumor volume in pancreatic cancer in the field of cancer biology remains uncertain. Rat anti-human TF monoclonal antibodies were prepared in our laboratory and were used in a chemiluminescent enzyme immunoassay (CLEIA) for TF detection. In an in vitro experiment, the antibodies for human TF did not crossreact with mouse TF. Therefore, tumor-derived TF was specifically detected using a novel sensitive human TF detection system developed for this study. The plasma concentration of tumor-derived TF was positively correlated with the tumor volume in mice bearing the human pancreatic cancer cell line BxPC-3. Thus, the plasma TF concentration may be a useful tumor marker. These data warrant further preclinical and clinical investigations of our CLEIA system.

Keywords